
Overview
Robyn Gartrell, MD, MS is a physician-scientist and pediatric oncologist who joined the faculty at Johns Hopkins University School of Medicine as Assistant Professor in January 2024. Dr. Gartrell completed her clinical pediatric hematology/oncology fellowship at New York Presbyterian / Columbia University Irving Medical Center (CUIMC), and a postdoctoral fellowship in Immunotherapy and Precision Medicine. She also completed a Master of Science in Patient Oriented Research as well as her first 5 years as faculty at CUIMC. Dr. Gartrell’s primary research focuses on combination approaches including radiation, chemotherapy, and other target agents with immunotherapy to improve response, increase survival, and decrease toxicity for children, adolescents, and young adults with cancer. Her laboratory uses advances in tumor immunology to develop more effective and more personalized therapies using multiplex platforms and immunogenomics to evaluate the tumor microenvironment and determine which pediatric tumor types, and which patients, will respond to immunotherapy.
Dr. Gartrell is rated as an Experienced provider by MediFind in the treatment of Rhabdomyosarcoma. Her top areas of expertise are Glioma, Diffuse Midline Glioma H3 K27M-Mutant, HER2 Negative Breast Cancer, and Pancreatic Ductal Adenocarcinoma.
Her clinical research consists of co-authoring 49 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
Locations
1800 Orleans Street, Bloomberg 11N, Bloomberg 11N, Baltimore, MD 21287
Additional Areas of Focus
Dr. Gartrell has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Johns Hopkins Children's Center
Dr. Christine Pratilas is a pediatric medical oncologist at the Sidney Kimmel Comprehensive Cancer Center and Associate Professor of Oncology, Pediatrics & Cellular and Molecular Medicine at the Johns Hopkins University School of Medicine. She joined the Hopkins pediatric sarcoma team in 2014. Dr. Pratilas received her undergraduate degree in Biology from Drew University in New Jersey and her medical degree from UMDNJ - Robert Wood Johnson Medical School (now Rutgers University), where she also completed her internship and residency from 1999 to 2002. From 2002 to 2005 she was a fellow in hematology and oncology in the Memorial Sloan Kettering Cancer Center (MSKCC) Department of Pediatrics, and in the Department of Pediatric Hematology and Oncology at New York Weill Cornell Medical Center. She was a postdoctoral research fellow in Dr. Neal Rosen’s Molecular Oncogenesis Laboratory at MSKCC. From 2006 to 2014 she was attending in Pediatric Oncology at MSKCC, specializing in developmental therapeutics & sarcoma. She has been the director of the pediatric sarcoma program at Hopkins since 2018. Dr. Pratilas focuses her research on cancer-associated pathways and signal transduction, which involves figuring out how a cell’s internal molecular pathways work, and how those pathways can be molecularly controlled. This knowledge is the basis for developing promising new molecularly targeted cancer therapies, which is the focus of Dr. Pratilas’s research. Among her important scientific contributions is advancing our understanding of how certain proteins that can be mutated in cancer, known as RAF kinases (specifically BRAF), affect a cancer cell’s behavior. The research in Dr. Pratilas' laboratory is focused on RAS signal transduction pathways, concentrating on pediatric sarcomas such as rhabdomyosarcoma and malignant peripheral nerve sheath tumors, in order to develop novel therapeutics for children with these tumors. Dr. Pratilas is rated as a Distinguished provider by MediFind in the treatment of Rhabdomyosarcoma. Her top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Adult Soft Tissue Sarcoma, and Osteotomy.
Jeffrey Dome is a Pediatric Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Dome is rated as an Advanced provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Rhabdoid Tumor, Denys-Drash Syndrome (DDS), Adult Soft Tissue Sarcoma, Nephrectomy, and Bone Marrow Aspiration.
Johns Hopkins Children's Center
Dr. Cohen is Director of Pediatric Neuro-Oncology and Clinical Director of the Division of Pediatric Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He received his undergraduate degree at Brown University and earned his MD at the Upstate Medical University, in Syracuse, NY. He did his general Pediatric Residency and Chief Residency at the University of Colorado and completed his Pediatric Hematology/Oncology Fellowship at Johns Hopkins. He has served on the faculty since 1994. His research centers on clinical trials of novel therapeutics for children with brain tumors. Dr. Cohen is co-chair of the High-Grade Glioma committee for the Children's Oncology Group and in that capacity has a particular research interest in the development of therapeutics for the treatment of infiltrating gliomas. He serves on the scientific advisory board for a number of organizations including St. Baldricks and the Childhood Brain Tumor Foundation. He is on the editorial board for PDQ with responsibility for authorship of the pediatric CNS brain tumor summaries. The Pediatric Neuro-Oncology program conducts a broad range of research centered primarily around the development and testing of novel therapeutics for children with brain tumors. The multidisciplinary nature of this work translates into continual collaboration with specialists in pediatric neurosurgery, radiation oncology, neuropathology, neuroradiology, neurology, neuro-ophthalmology, neuropsychology, and other related disciplines. Dr. Cohen is rated as a Distinguished provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Glioma, Medulloblastoma, Brain Stem Cancer, Embryonal Tumor with Multilayered Rosettes, and Bone Marrow Aspiration.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Diffuse Midline Glioma H3 K27M-MutantDr. Gartrell isAdvanced. Learn about Diffuse Midline Glioma H3 K27M-Mutant.
- GliomaDr. Gartrell isAdvanced. Learn about Glioma.
- HER2 Negative Breast CancerDr. Gartrell isAdvanced. Learn about HER2 Negative Breast Cancer.
- Experienced
- Acute Lymphoblastic Leukemia (ALL)Dr. Gartrell isExperienced. Learn about Acute Lymphoblastic Leukemia (ALL).
- Adult Soft Tissue SarcomaDr. Gartrell isExperienced. Learn about Adult Soft Tissue Sarcoma.
- Embryonal Tumor with Multilayered RosettesDr. Gartrell isExperienced. Learn about Embryonal Tumor with Multilayered Rosettes.
- HepatoblastomaDr. Gartrell isExperienced. Learn about Hepatoblastoma.
- Hereditary NeuroblastomaDr. Gartrell isExperienced. Learn about Hereditary Neuroblastoma.
- NeuroblastomaDr. Gartrell isExperienced. Learn about Neuroblastoma.

